Novartis to buy U.S.-based biotech CoStim for undisclosed price
ZURICH (Reuters) - Novartis said it will buy U.S.-based CoStim Pharmaceuticals Inc., a privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer, for an undisclosed price.
The Swiss drugmaker said the move follows increasing evidence pointing to the role of the immune system in controlling cancer.
(Reporting By Katharina Bart; Editing by John Stonestreet)
- Abbas-led Palestinian body backs Hamas truce demands in Gaza |
- UPDATE 4-Train carrying MH17 bodies reaches government-held Ukrainian city
- Rebels likely downed Malaysian jet 'by mistake': U.S. officials
- Islamic State crushes and coerces on march towards Baghdad
- Microsoft sees end to Nokia losses, shares rise after hours
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video